Invest In A Future Without Dementia
Alzheimer's Australia today, released a report 'Australian Dementia Research' that recommends annual funding for dementia research be increased three-fold to $36 million in response to the growing economic and social impact of the dementia epidemic.Prepared by the Dementia Collaborative Research Centre at the University of NSW, the report concludes that current investment over the last six years in dementia research was about $13 million, 0.
Advance Towards Early Alzheimer's Diagnosis
The leader of the team that made the discovery, Professor Christopher Rowe of the Austin Hospital in Melbourne, says early diagnosis and treatment presents medical practitioners with the best opportunity to delay the onset of Alzheimer's."While the discovery is at an experimental stage, this work places Australia at the forefront of neuro-imaging in Alzheimer's disease, " Professor Rowe says.
Suven Life Sciences Initiates Phase I Clinical Trials In Europe Of SUVN-502 For Alzheimer's Disease
Suven Life Sciences Ltd, a Drug Discovery and development company announced at Bio-2008, San Diego that they commenced Phase I clinical trials of SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson, Schizophrenia.
Elan And Wyeth Announce Encouraging Top-line Results From Phase 2 Clinical Trial Of Bapineuzumab For Alzheimer's Disease
Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) announced encouraging preliminary findings from a Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer's disease. In the 18-month trial, bapineuzumab appeared to have clinical activity in treating Alzheimer's disease. Efficacy FindingsThe study did not attain statistical significance on the primary efficacy endpoints in the overall study population.
Molecular Imaging Sheds New Light On Progression Of Alzheimer's Disease
In the past, physicians were able only to follow the progression of Alzheimer's disease (AD) through careful clinical histories, noting the often subtle changes associated with cognitive decline over a number of years.
UQ-US Team Targets Faster Alzheimer's Detection
Early detection of Alzheimer's Disease is in the sights of University of Queensland (UQ) scientists who have secured $1.6 million for new research. The UQ experts will work with peers at the Medical University of South Carolina to develop urgently-needed methods for early diagnosis of Alzheimer's Disease, which is the main form of dementia and afflicts more than 26 million people.
Known Genetic Risk For Alzheimer's In Whites Also Places Blacks At Risk
A commonly recognized gene that places one at risk for Alzheimer's disease does not discriminate between blacks and whites, according to new research led by Florida State University. FSU Psychology Professor Natalie Sachs-Ericsson and graduate student Kathryn Sawyer have found that the gene APOE epsilon 4 allele is a risk factor for African-Americans as well as whites. Until now, it has been a mainstream belief that the gene is only a risk factor for whites.
Researchers Link Memory Loss To Poor Diet
Loss of memory with advanced age is a significant problem within most societies, and appears particularly severe in advanced industrialized nations. A less visible and often ignored problem comes from a food supply high in cholesterol and saturated fat, which has led to high obesity rates particularly in the United States.
New Campaign Launched In Wales: Are You Worried About Your Memory?
Alzheimer's Society launches a new public information campaign in Wales to raise awareness of dementia, its symptoms and the importance of getting an early diagnosis. Called Worried About Your Memory?, the campaign will prompt and help people to consider if their forgetfulness, or that of a friend or relative, is due to just poor memory or the beginning of a medical problem and encourage them to seek medical advice.
The APCs Of Nerve Cell Function
Rapid information processing in the nervous system requires synapses, specialized contact sites between nerve cells and their targets. One particular synapse type, cholinergic, uses the chemical transmitter acetylcholine to communicate between nerve cells. Cholinergic synapses are essential for normal learning and memory, arousal, attention, and all autonomic (involuntary) nervous system functions.